RETRACTED: Endogenous production of C-C motif chemokine ligand 2 by nasopharyngeal carcinoma cells drives radioresistance-associated metastasis

Cancer Lett. 2020 Jan 1:468:27-40. doi: 10.1016/j.canlet.2019.10.008. Epub 2019 Oct 8.


This article has been retracted: please see Elsevier Policy on Article Withdrawal ( This article has been retracted at the request of the Editor-in-Chief. Following the publication of the above article, the Editor was notified by a concerned reader that the authors supplied duplicated images. Specifically, overlap in Figures 1C, 4A, 4B, 4D, and 5C. These concerns were also reported at PubPeer After review, the Editor found that duplication did occur and therefore the decision was made to retract the article. After re-examination of the entire paper, raw data and lab records, the authors have found that “pictures between different experiments were carelessly mixed. We want to apologize for all the inconvenience it caused to the editorial board, and to all our peers and to all the readers of our paper.”

Keywords: C–C motif chemokine ligand 2; Epithelial-mesenchymal transition; Metastasis; Nasopharyngeal carcinoma; Radioresistance.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Adult
  • Autocrine Communication
  • Cell Line, Tumor
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism*
  • Chemoradiotherapy / methods
  • Cisplatin / therapeutic use
  • Disease-Free Survival
  • Epithelial-Mesenchymal Transition
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma / mortality
  • Nasopharyngeal Carcinoma / pathology
  • Nasopharyngeal Carcinoma / therapy*
  • Nasopharyngeal Neoplasms / mortality
  • Nasopharyngeal Neoplasms / pathology
  • Nasopharyngeal Neoplasms / therapy*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm Recurrence, Local / radiotherapy
  • Organoplatinum Compounds / therapeutic use
  • Prognosis
  • Progression-Free Survival
  • Radiation Tolerance*
  • Signal Transduction
  • Tumor Suppressor Protein p53 / metabolism
  • Xenograft Model Antitumor Assays


  • CCL2 protein, human
  • Chemokine CCL2
  • Organoplatinum Compounds
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • nedaplatin
  • Cisplatin